Preventing congenital anomalies in developing countries

Community Genetics

Volumn 5, Issue 1, 2002, Pages 61-69

  Penchaszadeh, Victor B ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Birth defects; Congenital anomalies; Developing countries; Prevention

Indexed keywords

ALCOHOL; FOLIC ACID; MISOPROSTOL; THALIDOMIDE;

ARTICLE; BIRTH DEFECT; CONGENITAL MALFORMATION; CONGENITAL RUBELLA SYNDROME; CONGENITAL SYPHILIS; DEVELOPING COUNTRY; DOWN SYNDROME; DRUG EFFECT; EMBRYOPATHY; ENVIRONMENTAL EXPOSURE; FAMILY PLANNING; FETUS MALFORMATION; FOLIC ACID DEFICIENCY; GENE MUTATION; GENETIC DISORDER; HEALTH CARE PERSONNEL; HEALTH EDUCATION; HUMAN; IMMUNIZATION; INFORMATION SERVICE; INTRAUTERINE INFECTION; IODINATION; IODINE DEFICIENCY; MOEBIUS SYNDROME; PRENATAL CARE; PRENATAL SCREENING; PRESCRIPTION; PREVALENCE; PREVENTIVE MEDICINE; PRIMARY HEALTH CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; PUBLIC HEALTH; REPRODUCTION; RISK FACTOR; SECONDARY PREVENTION; SUPPLEMENTATION; TERATOGENICITY;

EID: 0036428312     PISSN: 14222795     EISSN: None     Source Type: Journal    
DOI: 10.1159/000064632     Document Type: Article

References (67)

1. Penchaszadeh VB: Implementing genetic services in developing countries. The case of Latin America; in Kuliev A, Greendale K, Penchas-zadeh V, Paul NW (eds): Genetic Services Provision: An International Perspective. Birth Defects Original Article Ser 1992;28:17-26.
2. WHO: Prevention and Care of Genetic Diseases and Birth Defects in Developing Countries (WHO/HGN/GL/WAOPBD/99.1). Geneva, WHO, 1999.
3. WHO: Primary Health Care Approaches for Prevention and Control of Congenital and Genetic Disorders (WHO/HGN/WG/00.1). Geneva, WHO, 2000.
4. Penchaszadeh VB: Delivery of genetic services in developing countries; in Khoury MJ, Burke W, Thompson E (eds): Genetics and Public Health in the 21st Century. New York, Oxford University Press, 2000, pp 301-327.
5. Leck I, Record RG, McKeown T, et al: The incidence of malformations in Birmingham, England, 1950-1959. Teratology 1968;1:263.
6. International Clearinghouse for Birth Defects Monitoring Systems: Congenital Malformations Worldwide. A Report from the International Clearinghouse for Birth Defects Monitoring Systems. Amsterdam, Elsevier, 1991.
7. International Clearinghouse for Birth Defects Monitoring Systems, WHO, EUROCAT: World Atlas of Birth Defects, ed 1. Geneva, WHO, 1998.
8. UNICEF: The State of the World's Children. Early Childhood. New York, UNICEF, 2000.
9. WHO Advisory Group on Hereditary Diseases: Community Approaches to the Control of Hereditary Diseases. Geneva, WHO, 1985.
10. Xiao KZ, Zhang ZY, Su YM, et al: Central nervous system congenital malformations, especially neural tube defects in 29 provinces, metropolitan cities and autonomous regions of China: Chinese Birth Defects Monitoring Program. Int J Epidemiol 1990;19:978-982.
11. Mutchinick O, Lisker R, Rabinsky V: The Mexican Program of Registration and Epidemiologic Surveillance of External Congenital Malformations (SPA). Salud Publica Mex 1988;30:88-100.
12. Saborio M. Experience in providing genetic services in Costa Rica; in Kuliev A, Greendale K, Penchaszadeh VB, Paul NW (eds): Genetic Services Provision: An International Perspective. Birth Defects Original Article Ser 1992; 28:96-102.
13. Nazer JH, Lopez-Camelo J, Castilla EE: ECLAMC: Results of thirty years of epidemiological surveillance of neural tube defects. Rev Méd Chile 2001;129:531-539.
14. Xiao KZ, Lang ZC, Chen JH, Liu SL, et al: Consecutive three-year birth defects monitoring in Sichuan province. Heredity Dis 1988;5: 65-68.
15. Castilla EE, Orioli IM: Prevalence rates of microtia in South America. Int J Epidemiol 1986; 15:364-368.
16. Modell B, Boulyjenkov V: Distribution and control of some genetic disorders. World Health Stat Q 1988;41:209-218.
17. Castilla EE, Lopez-Camelo JS: The surveillance of birth defects in South America. 1. The search for time clusters: Epidemics. Ad Mutagen Res 1990;2:191-210.
18. Venter PA, Christianson AL, Hutamo CM, Makhura MP, Gericke GS: Congenital anomalies in rural black South African neonates - A silent epidemic? S Afr Med J 1995;85:15-20.
19. Carothers AD, Hecht CA, Hook EB: International variation in reported livebirth prevalence rates of Down syndrome, adjusted for maternal age. J Med Genet 1999;36:386-393.
20. WHO Scientific Group: Control of hereditary diseases. Report of a WHO Scientific Group. Geneva, WHO Technical Report Series 1996, No. 865.
21. Castilla EE: Reproduction age as risk factor for birth defects. Braz J Genet 1996;19(suppl):92.
22. United Nations Fund for Population Activities: The State of World Population 1998. New York, United Nations Fund for Population Activities, 1998.
23. Schuler-Faccini L, Leite JCL, Vieira-Sanseverino MT, Mizunski-Peres R: Evaluation of potential teratogens in Brazilian population. Cienc Saude Colectiva 2002, in press.
24. Cutts FT, Robertson SE, Diaz-Ortega JL, Samuel R: Control of rubella and congenital rubella syndrome (CRS) in developing countries. 1. Burden of disease from CRS. Bull World Health Organ 1997;75:55-68.
25. Cutts FT, Wynnyck E: Modelling the incidence of congenital rubella syndrome in developing countries. Int J Epidemiol 1997;28:1176-1184.
26. Murray C, Lopez A (eds): The Global Burden of Disease. Cambridge, Harvard School of Public Health, 1996.
27. McDermott J, Steketee R, Larsen S, Wirima J: Syphilis-associated perinatal and infant mortality in rural Malawi. Bull World Health Organ 1993;71:773-780.
28. World Bank: Confronting AIDS. Public Priorities in a Global Epidemic. New York, Oxford University Press, 1997.
29. Castilla EE, Ashton-Prolla P, Barreda-Mejia E, Brunoni D, et al: Thalidomide, a current teratogen in South America. Teratology 1996:54: 273-277.
30. D'Amato RJ, Luoghnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91: 4082-4085.
31. Schuler L, Sanseverino MT, Clavijo HA, Ashton-Prolla P, et al: Preliminary report on the first Brazilian teratogen information service (SIAT). Braz J Genet 1993;16:1085-1095.
32. Costa SH, Vessey MP: Misoprostol and illegal abortion in Rio de Janeiro, Brazil. Lancet 1993;341:1258-1261.
33. Coelho HLL, Teixeira AC, Santos AP, et al: Misoprostol and illegal abortion in Fortaleza, Brazil. Lancet 1993;341:1261-1263.
34. Pastuszak AL, Schuler L, Speck-Martins CE, Coelho KEFA, Cordello SM, Vargas F, Brunoni D, Schwarz IVD, Larrandaburu M, Safattle H, Meloni VFA, Koren G: Use of misopros-tol during pregnancy and Moebius' syndrome in infants. N Engl J Med 1998;338:1881-1885.
35. Schuler L, Pastuszak A, Sanseverino TV, Orioli IM, et al: Pregnancy outcome after exposure to misoprostol in Brazil: A prospective, controlled study. Reprod Toxicol 1999;13:147-151.
36. Shepard TH: Catalog of Teratogenic Agents, ed 8. Baltimore, Johns Hopkins University Press, 1995.
37. Holmes LB, Harvey EA, Coull BA, Huntington KB, Khosibin S, Hayes AM, Ryan LM: The teratogenicity of anticonvulsant drugs. N Engl J Med 2001;344:1132-1138.
38. Viljoen D: Fetal alcohol syndrome. S Afr Med J 1999;89:958-960.
39. Croxford J, Viljoen D: Alcohol consumption by pregnant women in the Western Cape. S Afr Med J 1999;89:962-965.
40. May PA, Brooke L, Gossage JP, Croxford J, Adnams C, Jones KL, Robinson L, Viljoen D: Epidemiology of fetal alcohol syndrome in a South African community in the Western Cape Province. Am J Public Health 2000;90:1905-1912.
41. Warren KR, Calhoun FJ, May PA, Viljoen DL, Li TK, Tanaka H, Marinicheva GS, Robinson LK, Mundle G: Fetal alcohol syndrome: An international perspective. Alcohol Clin Exp Res. 2001 May;25(suppl ISBRA):202S-206S.
42. Pharoah PO: Iodine-supplementation trials. Am J Clin Nutr 1993;57(suppl):276S-279S.
43. Maberly G: Iodine deficiency. Bull World Health Organ 1998;76(suppl 2):118-120.
44. Czeizel AE, Dudás I: Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. N Engl J Med 1992;327:1832-1835.
45. Penchaszadeh VB, Christianson AL, Giugliani R, Boulyjenkov, Katz M: Services for the prevention and management of genetic disorders and birth defects in developing countries. Community Genet 1999;2:196-201.
46. Penchaszadeh VB: Community genetics in Latin America: Challenges and perspectives. Community Genet 2000;3:124-127.
47. Penchaszadeh VB, Beiguelman B: Medical genetics services in Latin America: Report of a meeting of experts. Pan Am J Public Health 1998;3:409-420.
48. Robertson SE, Cutts FT, Samuel R, et al: Control of rubella and congenital rubella syndrome (CRS) in developing countries. 2. Vaccination against rubella. Bull World Health Organ 1997; 75:55-68.
49. Pan American Health Organization: Report on Vaccines and Immunization. 128th Session of the Executive Committee, 25-29 June 2001. Washington, PAHO, 2001, pp 10-11.
50. Smithells RW, Sheppard S, Schorah CJ, et al: Apparent prevention of neural tube defects by vitamin supplementation. Arch Dis Child 1981;56:911.
51. MRC Vitamin Study Research Group: Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study. Lancet 1991;338:131-137.
52. Anonymous: Recommendations for the use of folic acid to reduce the number of cases of spi-na bifida and other neural tube defects. MMWR Recomm Rep 1992;41(RR-14):1-7.
53. Cornel MC, Erickson JD: Comparison of national policies on periconceptional use of folic acid to prevent spina bifida and anencephaly. Teratology 1997;55:134-137.
54. Berry RJ, Zhu I, Erickson JD, Song I, et al: Prevention of neural tube defects with folic acid in China. N Engl J Med 1999;341:1485-1490.
55. Cuba Neuropathy Investigation Team: Epidemic optic neuropathy in Cuba: Clinical characterization and risk factors. N Engl J Med 1995;333:1176-1182.
56. Rodriguez L, Sanchez R, Hernandez J, Carrillo L, et al: Results of 12 years of combined maternal serum α-fetoprotein screening and ultrasound fetal monitoring for prenatal detection of fetal malformations in Havana City, Cuba. Prenat Diagn 1997;4:301-304.
57. Stanbury JB: Prevention of iodine deficiency; in Howson CP, Kennedy ET, Horowitz A (eds): Prevention of Micronutrient Deficiencies: Tools for Policymakers and Public Health Workers. Washington, National Academy Press, 1998.
58. Delange F, de Beoist B, Pretell E, Dunn JT: Iodine deficiency in the world: Where do we stand at the turn of the century? Thyroid 2001; 11:437-447.
59. Heredero L: Comprehensive national genetic program in a developing country - Cuba; in Kuliev A, Greendale K, Penchaszadeh VB, Paul NW (eds): Genetic Services Provision: An International Perspective. Birth Defects Original Article Ser 1992;2852-2857.
60. Heredero L: Medical genetic services in Cuba; in Penchaszadeh VB, Beiguelman B (eds): Medical Genetic Services in Latin America 1998. Geneva, WHO, 1998 (WHO/HGN/ CONS/MGS/98.4).
61. Lo WHY: Medical genetics in China. J Med Genet 1988;25:253-257.
62. Ren A, Li Z: Current status of genetic counseling in the prevention of birth defects in China. Proceed Int Conf Birth Defects Disabilities Dev World, August 6-10, 2001, Johannesburg, South Africa, p 32.
63. Jenkins T: Medical genetics in South Africa. J Med Genet 1990;27:760-779.
64. Viljoen D, Beighton P, Hitseroth: Medical genetics in primary health care. S Afr Med J 1995;85:1-3.
65. Christianson AL, Venter PA, Modiba JH, Nelson MM: Development of a primary health care clinical genetic service in rural South Africa. The Northern Province experience, 1990-1996. Community Genet 2000;3:77-84.
66. Department of Health, South Africa: Human Genetic Policy Guidelines for the Management and Prevention of Genetic Disorders, Birth Defects and Disabilities. Pretoria, Department of Health, 2001.
67. Unpublished WHO document 1985;HMG/AG/85.10. Geneva, WHO.